Mr. Ibrahem/Alfuzosin
Clinical data
Pronunciation/ælˈfjuːzsɪn/ al-FEW-zoh-sin
Trade namesUroxatral, others
AHFS/Drugs.comMonograph
MedlinePlusa64002
Pregnancy
category
  • AU: B2
Routes of
administration
By mouth (tablets)
Drug classα1 adrenergic receptor blocker[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability49%
Protein binding82–90%
MetabolismLiver (CYP3A4-mediated)
Elimination half-life10 hours
ExcretionFeces (69%) and Urine (24%)
Identifiers
  • (RS)-N-[3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Chemical and physical data
FormulaC19H27N5O4
Molar mass389.456 g·mol−1
3D model (JSmol)
  • O=C(NCCCN(c2nc1cc(OC)c(OC)cc1c(n2)N)C)C3OCCC3
  • InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23) checkY
  • Key:WNMJYKCGWZFFKR-UHFFFAOYSA-N checkY
  (verify)

Alfuzosin, sold under the brand name Uroxatral among others, is a medication used to treat benign prostatic hyperplasia (BPH).[1] It may be less effective than other medications in its class.[2] It may be used together with a 5α-reductase inhibitors.[1] It is taken by mouth once per day.[1]

Common side effects include lightheadedness, tiredness, and headache.[1] Other side effects include low blood pressure and QT prolongation.[1] Use is not recommended in those with significant liver problems.[1] It is a α1 adrenergic receptor blocker and works by relaxing the muscles in the prostate and bladder neck.[1]

Alfuzosin was patented in 1978 and approved for medical use in 1988.[3] It was approved for medical use in the United States in 2003.[1] In the United States it costs about 18 USD for 3 months.[4] In 2017, it was the 266th most commonly prescribed medication in the United States, with more than one million prescriptions.[5][6]

References edit

  1. ^ a b c d e f g h i j k "Alfuzosin Monograph for Professionals". Drugs.com. Archived from the original on 19 January 2021. Retrieved 14 July 2021.
  2. ^ Lepor H (August 2016). "Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia". The Urologic Clinics of North America. 43 (3): 311–23. doi:10.1016/j.ucl.2016.04.009. PMC 2213889. PMID 27476124.
  3. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 455. ISBN 9783527607495. Archived from the original on 2020-10-05. Retrieved 2020-09-19.
  4. ^ "Alfuzosin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 5 July 2017. Retrieved 14 July 2021.
  5. ^ "The Top 300 of 2020". ClinCalc. Archived from the original on 18 March 2020. Retrieved 11 April 2020.
  6. ^ "Alfuzosin Hydrochloride - Drug Usage Statistics". ClinCalc. Archived from the original on 12 April 2020. Retrieved 11 April 2020.